Last reviewed · How we verify
Placebo First, then ORADUR®
ORADUR is a sustained-release formulation of buprenorphine.
ORADUR is a sustained-release formulation of buprenorphine. Used for Moderate to severe pain.
At a glance
| Generic name | Placebo First, then ORADUR® |
|---|---|
| Also known as | Placebo |
| Sponsor | Orient Pharma Co., Ltd. |
| Drug class | Opioid partial agonist |
| Target | Opioid receptors |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 3 |
Mechanism of action
ORADUR works by releasing buprenorphine slowly over time, providing long-lasting pain relief. Buprenorphine is a partial opioid agonist that binds to opioid receptors in the brain, reducing the perception of pain.
Approved indications
- Moderate to severe pain
Common side effects
- Nausea
- Vomiting
- Dizziness
- Headache
- Constipation
- Diarrhea
- Fatigue
- Insomnia
- Sedation
- Withdrawal symptoms
Key clinical trials
- Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo First, then ORADUR® CI brief — competitive landscape report
- Placebo First, then ORADUR® updates RSS · CI watch RSS
- Orient Pharma Co., Ltd. portfolio CI